Stayble Therapeutics AB
Develops an injectable drug for lumbar disc herniation pain as an alternative to surgery.
STABL | ST
Overview
Corporate Details
- ISIN(s):
- SE0013513652 (+1 more)
- LEI:
- 549300WD23DE1US21868
- Country:
- Sweden
- Address:
- Lennart Torstenssonsgatan 6, 412 56 Göteborg
- Website:
- https://staybletherapeutics.com/
- Sector:
- Manufacturing
- Industry:
- Manufacture of pharmaceuticals, medicinal chemical and botanical products
Description
Stayble Therapeutics AB is a clinical-stage pharmaceutical company focused on developing treatments for pain caused by lumbar disc herniation (LDH). The company's lead drug candidate, STA363, is a minimally invasive, injection-based therapy. It is designed as a second-line treatment for patients who do not find relief from conservative options like physiotherapy and analgesics. STA363 aims to bridge the therapeutic gap between conservative care and invasive surgery, offering a novel solution for individuals with sustained, disabling pain. The company's strategy involves advancing the candidate through clinical trials to become a market leader in this therapeutic area.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| No filings match the current criteria. | |||||
Automate Your Workflow. Get a real-time feed of all Stayble Therapeutics AB filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
No Financial Data Available
Standardized financial statements for the selected period are not yet available.
Need More History? Access decades of standardized financials for Stayble Therapeutics AB via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
